G-CSF & GM-CSF Product description The present Competitive Intelligence Report about G-CSF & GM-CSF products in the pipeline and off-patent products provides a competitor evaluation in the field of G-CSF & GM-CSF branded products, off-patent products, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products or new uses of G-CSF as of May 2008. The report includes a compilation of currently marketed branded and off-patent G-CSF and GM-CSF proudcts for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2007. It lists the most advanced biosimilars of G-CSF and pegylated G-CSF and of GM-CSF. It describes the companies with G-CSF and GM-CSF products and of pegylated versions in off-patent countries. Competitor projects are listed in a tabular format providing Information on: - Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index - 2007 Market of branded G-CSF products
- Biosimilar G-CSF products
- Next generation G-CSF products and uses
- Off-patent G-CSF products
- Off-patent pegylated G-CSF products
- Branded GM-CSF products
- Off-patent and follow-up GM-CSF products
- About La Merie
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
